6 results on '"Innocenzi M"'
Search Results
2. Deficient Emotional Self-Regulation in ADHD Assessed Using a Unique Profile of the Child Behavior Checklist (CBCL): Replication in an Italian Study.
- Author
-
Donfrancesco R, Innocenzi M, Marano A, and Biederman J
- Subjects
- Adolescent, Aggression psychology, Case-Control Studies, Child, Child Behavior, Female, Humans, Italy, Male, Psychiatric Status Rating Scales, ROC Curve, Sensitivity and Specificity, Attention Deficit Disorder with Hyperactivity psychology, Checklist statistics & numerical data, Emotions, Self-Control
- Abstract
Objective: A unique profile of the empirically derived Child Behavior Checklist-anxious/depressed, attention, and aggression-deficient emotional self-regulation (CBCL-AAA-DESR profile: ≥180 and ≤210) may be used to identify a sizable minority of children with ADHD with associated DESR. The main aim of this study was to replicate these findings in an Italian sample., Method: The sample consisted of 358 children and teenagers aged 6 to 17 years of both sexes with (n = 190) and without a diagnosis of ADHD (n = 168)., Results: In all, 40.0% of children with ADHD had a positive CBCL-DESR profile compared with 3.5% of controls. Receiver-operating characteristic analysis showed that the CBCL-DESR profile cut-off (sensitivity = 97.33, specificity = 79.66, criterion ≥179, ≤210) discriminated the two subsamples., Conclusion: The findings replicate previous results highlighting the utility of the CBCL as a means of identifying DESR in children with ADHD., (© 2012 SAGE Publications.)
- Published
- 2015
- Full Text
- View/download PDF
3. [Prostate cancer unit for an optimal management of prostate cancer unit].
- Author
-
Sciarra A, Salciccia S, Gentilucci A, Innocenzi M, Alfarone A, Cattarino S, Ravaziol M, and Panebianco V
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma epidemiology, Disease Management, Early Diagnosis, Humans, Incidence, Interdisciplinary Communication, Male, Patient Care Team, Prostatic Neoplasms diagnosis, Prostatic Neoplasms epidemiology, Adenocarcinoma therapy, Hospital Units organization & administration, Prostatic Neoplasms therapy
- Abstract
Prostate cancer (PC) is established as one of the most important medical problems affecting the male population. PC is the most common solid neoplasm (214 cases per 1000 men) and the second most common cause of cancer death in men. Its management involves several complex issues for both clinicians and patients. An early diagnosis is necessary to implement well-balanced therapeutic options, and the correct evaluation can reduce the risk of overtreatment with its consequential adverse effects. Breast and Prostate cancers, respectively, are the most common cancers in women and in men, and different similarities have been underlined. The paradigm of the patient consulting a multidisciplinary medical team has been an established standard approach in treating breast cancer. Such multidisciplinary approach can offer the same optional care for men with PC as it does for women with breast cancer. A multidisciplinary team (MDT) comprises healthcare professionals from different disciplines whose goal of providing optimal patient care is achieved through coordination and communication with one another. A Prostate Cancer Unit is a place where men can be cared for by specialists in PC, working together within a multi-professional team. The MTD approach guarantees a higher probability for the PC patient to receive adequate information on the disease and on all possible therapeutic strategies, balancing advantages and related side effects. The future of PC patients relies on a successful multidisciplinary collaboration between experienced physicians, which can lead to important advantages in all the phases and aspects of PC management.
- Published
- 2012
- Full Text
- View/download PDF
4. [Current diagnostic procedure on neuroendocrine differentiation of prostate cancer].
- Author
-
Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Panebianco V, Buonocore V, Gentile V, and Di Silverio F
- Subjects
- Carcinoma metabolism, Contrast Media, Diagnosis, Differential, Gene Expression Regulation, Neoplastic, Humans, Magnetic Resonance Spectroscopy methods, Male, Neuroendocrine Tumors metabolism, Prostatic Neoplasms metabolism, Reverse Transcriptase Polymerase Chain Reaction, Risk Assessment, Risk Factors, Somatostatin analogs & derivatives, Biomarkers, Tumor blood, Carcinoma blood, Carcinoma diagnosis, Chromogranin A blood, Neuroendocrine Tumors blood, Neuroendocrine Tumors diagnosis, Prostatic Neoplasms blood, Prostatic Neoplasms diagnosis
- Abstract
Chromogranin A (CgA) is considered as a major specific neuroendocrine tumor marker. It belongs to the secretogranin family, which is present in the gastrointestinal tract, respiratory system, endocrine glands and in a group of endocrine cells such us pancreas and thyroid. Serum levels of CgA could reflect the neuroendocrine activity and could be used when evaluating advance prostate carcinoma. Moreover, there are also several factors that may increase the serum level of CgA: treatment with proton-pump inhibitors or H2-receptor blockers, chronic atrophic gastritis, rheumatoid arthritis, liver and renal failure. Another method to evaluate NE differentiation is scintigraphy with the 111In-labeled somatostatin analogue (DTPA-D-Phe)-octrotide, (Octreoscan). This method takes advantage of the overexpression of type II somatostatin receptors on the cell surface of NE tumors. With this technique the presence of NE differentiation can be detected both at the primary (prostate) and the metastatic sites. A more specific system to detect NE cell activity is obtained by analyzing CgA gene expression in prostate tissue by a semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR).
- Published
- 2011
- Full Text
- View/download PDF
5. [Neuroendocrine target therapies for prostate cancer].
- Author
-
Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Monti G, Gentile V, and Di Silverio F
- Subjects
- Biomarkers, Tumor blood, Chromogranin A blood, Chromogranin A drug effects, Disease Progression, Ethinyl Estradiol administration & dosage, Humans, Male, Neuroendocrine Tumors blood, Peptides, Cyclic administration & dosage, Prostatic Neoplasms blood, Somatostatin administration & dosage, Somatostatin analogs & derivatives, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neuroendocrine Tumors drug therapy, Prostatic Neoplasms drug therapy
- Abstract
It is important to determine whether an increase in Chromogranin A levels and neuroendocrine (NE) cell activation are associated with progression towards on hormone-independent prostate-cancer. We proposed a combination of estrogens and somatostatin analogues as therapy of NE activation in hormone-independent prostate cancer. The combined therapy with ethinyl estradiol and lanreotide offered objective and symptomatic responses in patients with limited treatment options and refractoriness to conventional hormonal therapy strategies; in particular, it offered a median overall survival that was superior to the 10-month median survival in patients with hormone refractory disease. This combined therapy also sustains the new concept in cancer treatment in which therapies may target not only cancer cells but also its microenvironment, which can yield protection against apoptosis.
- Published
- 2011
- Full Text
- View/download PDF
6. [Role of neuroendocrine cells in prostate cancer progression].
- Author
-
Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Panebianco V, Buonocore V, Gentile V, and Di Silverio F
- Subjects
- APUD Cells metabolism, Adenocarcinoma drug therapy, Adenocarcinoma pathology, Adult, Antineoplastic Agents, Hormonal therapeutic use, Calcitonin metabolism, Cell Transformation, Neoplastic drug effects, Chorionic Gonadotropin metabolism, Chromogranin B metabolism, Chromogranins metabolism, Diagnosis, Differential, Disease Progression, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neuroendocrine Cells drug effects, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors pathology, Nuclear Proteins metabolism, Parathyroid Hormone-Related Protein metabolism, Peptide Fragments metabolism, Peptide Hormones metabolism, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Serotonin metabolism, Transcription Factors metabolism, Treatment Failure, Adenocarcinoma metabolism, Biomarkers, Tumor metabolism, Chromogranin A metabolism, Neuroendocrine Cells metabolism, Neuroendocrine Tumors metabolism, Prostatic Neoplasms metabolism
- Abstract
Neuroendocrine (NE) cells represent the third epithelial cell type on normal prostatic tissue (in addition to basal and secretory cells). They are localized in all regions of the human prostate at birth but rapidly decrease in the peripheral prostate after birth, and then reappear at puberty. After puberty, their number seems to increase until an apparently optimum level is reached, which persists between the age of 25 and 54. NE cells were defined by Pearse as APUD to refer to chemical characteristics of amine precursor uptake and decarboxylation, common to the cells of this system. The most predominant product of prostatic NE cells is Chromogranin A, but they also produce serotonin, CgB, secretogranin or CgC, thyroid-stimulating hormone-like peptide, calcitonin, katacalcin, PTHrP and a-human chorionic gonadotropin-like peptide. NE cells in normal and neoplastic prostates are devoid of androgen receptors, but they express epidermal growth factor (EGF) receptor and c-erbB-2. For these reason NE cells are androgen-insensitive. The NE component of prostate adenocarcinoma is resistant to hormone therapy; some studies showed that the number of NE tumor cells and CgA serum levels increase with the recovery of human prostate tumor from hormonal therapy. Currently there are no clinical data available to support an active role of radiotherapy in NE differentiation.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.